ABSTRACT
Morgellons disease is a rare disease with unknown etiology. Herein, we report the first case of Morgellons disease in Korea. A 30-year-old woman presented with a 2-month history of pruritic erythematous patches and erosions on the arms, hands, and chin. She insisted that she had fiber-like materials under her skin, which she had observed through a magnifying device. We performed skin biopsy, and observed a fiber extruding from the dermal side of the specimen. Histopathological examination showed only mild lymphocytic infiltration, and failed to reveal evidence of any microorganism. The polymerase chain reaction for Borrelia burgdorferi was negative in her serum.
Subject(s)
Adult , Female , Humans , Arm , Asian People , Biopsy , Borrelia burgdorferi , Chin , Hand , Korea , Morgellons Disease , Nerve Fibers, Myelinated , Polymerase Chain Reaction , Rare Diseases , SkinABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Subject(s)
Humans , Acneiform Eruptions , Carcinoma, Non-Small-Cell Lung , Clindamycin , Dermatology , Drug Therapy , Epidermal Growth Factor , Minocycline , SkinABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Subject(s)
Humans , Acneiform Eruptions , Carcinoma, Non-Small-Cell Lung , Clindamycin , Dermatology , Drug Therapy , Epidermal Growth Factor , Minocycline , SkinABSTRACT
BACKGROUND: Home-use devices designed for cosmetic purposes have recently gained popularity. Small, low-energy, low-cost intense pulsed light (IPL) systems provide safe, convenient, and private treatment for several medical conditions. OBJECTIVE: In this study, we aimed to assess the efficacy and safety of a home-use IPL device for hair removal, acne treatment, achieving a whitening effect for hyperpigmentation, and wrinkle reduction. METHODS: Five IPL hair removal treatment sessions were performed at 1-week intervals. A total of 10 sessions were performed in a split-face manner for other medical conditions. Four independent randomized controlled trials were performed using a blind evaluation method. All subjects were followed up twice to evaluate the maintenance of efficacy. RESULTS: A significant reduction in hair was observed via trichoscopy following two sessions of treatment (p<0.001). A mean hair reduction of 80% was observed at week 4; however this returned to the previous state upon cessation of treatment. Acne grading decreased from 2.6 to 1.1 at week 8, and IPL treatment induced a significant reduction in melanin index after 2 weeks. The average values of the difference of R2 (Cutometer(R)) between IPL-treated areas and baseline were higher than those of the difference of R2 between control area and baseline. CONCLUSION: This home-use IPL device was effective for hair removal and treatment of acne, hyperpigmentation, and wrinkles.